tbuckley/cabot-search huggingface dataset:
P4.15A.01 Efficacy of Digital Therapeutics for the Perioperative Management in Patients with Lung Cancer: A Randomized Controlled Trial
Authors: J. Xu, H. Ni, H. Zhan, H. Yu, Z. Lu, J. Zhang, H. Meng, L. Hang, L. Mao, X. Xu, X. Ma, Q. Wu, W. Xu, D. Xiang, Y. Zeng, D. Meng, X. Teng, L. Yu, L. Zeng, P. Ni, H. Miao, S. Fu, L. Wang, Z. He, C. Zhang, X. Lv, H. Xu, Y. Wu, W. Lv, K. Chen, Q. Shi, J. Hu
Journal: Journal of Thoracic Oncology (2024)
P4.14C.04 Exhaled Breath Analysis for the Early Diagnosis of Malignant Pleural Mesothelioma and the Surveillance of Asbestos-Exposed At-Risk Subjects
Authors: A. Catino, A. Di Gilio, J. Palmisani, M. Nisi, N. Varesano, D. Galetta, G. De Gennaro
Journal: Journal of Thoracic Oncology (2024)
P4.11E.22 Treatment-Free Survival in Advanced NSCLC Patients who Terminated Immune-Checkpoint Inhibitors.
Authors: T. Nagai, H. Akamatsu, E. Takase, E. Murakami, T. Sugimoto, R. Shibaki, A. Hayata, T. Shimizu, M. Nakanishi, Y. Koh, N. Yamamoto
Journal: Journal of Thoracic Oncology (2024)
P4.14C.02 Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single Center Retrospective Study
Authors: T. Higashiyama, K. Kuribayashi, M. Murakami, N. Kawamura, T. Kondo, T. Fujioka, T. Kandori, M. Tokuda, Y. Negi, D. Fujimoto, T. Otsuki, K. Mikami, R. Takahashi, T. Minami, T. Kijima
Journal: Journal of Thoracic Oncology (2024)
P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs
Authors: K. Yin, L.-P. Chen, S.-Y.M. Liu, Q. Zhou, Y.-L. Sun, E.-E. Ke, Y.-S. Li, M.-M. Zheng, C.-R. Xu, J.-X. Lin, X.-Y. Bai, Z. Wang, H.-H. Yan, J.-J. Yang, H.-J. Chen, B.-C. Wang, H.-Z. Hong, W.-Z. Zhong, Y.-L. Wu, H.-Y. Tu
Journal: Journal of Thoracic Oncology (2024)
P4.14C.06 Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma
Authors: K. Mikami, T. Otsuki, D. Fujimoto, Y. Negi, A. Tada, T. Higashiyama, M. Tokuda, J. Kiyota, T. Kondo, T. Kandori, H. Oota, T. Murata, H. Wakita, M. Kato, M. Mori, R. Takahashi, T. Minami, K. Kuribayashi, T. Kijima
Journal: Journal of Thoracic Oncology (2024)
P4.11E.24 Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC
Authors: W. Dohi, H. Kanemura, J. Tanizaki, S. Suzuki, T. Takahama, K. Tanaka, T. Iwasa, K. Yoesaka, H. Hayashi
Journal: Journal of Thoracic Oncology (2024)
P4.15B.01 Remote Exercise Program for Patients with Lung Cancer on Immune Checkpoint Inhibitors
Authors: P.G. Bergerot, C.D. Bergerot, J.R.G. Silva, J.R. Farias, P.S.M. Lages, W.H. Fuzita, J.N. Matos Neto, M.V.d.S. França, M.M. Buso, M.T. Laloni, C.G. Ferreira, W.N. William, E. Soto-Perez-de-Celis, K.H. Schmitz, N. Florez
Journal: Journal of Thoracic Oncology (2024)
P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study
Authors: A. Miyazaki, K. Kunimasa, T. Morishima, T. Kawamura, T. Inoue, M. Tamiya, I. Miyashiro, K. Nishino
Journal: Journal of Thoracic Oncology (2024)
P4.14C.05 Incidence of Pseudoprogression and Hyperprogression in Patients with Pleural Mesothelioma Treated with Ipilimumab and Nivolumab
Authors: O. Mitchell, F. Li, C.M. Straus, G. Porroga, A.N. Husain, M.W. Drazer, S.G. Armato, H.L. Kindler
Journal: Journal of Thoracic Oncology (2024)
P4.11E.25 NSCLC Immune Hemogram Index (NIHX) A Predictive Score for Immunotherapy Response in PD-L1 Negative Advanced NSCLC
Authors: C.R. Picón, J.N. Minatta, M. Sanchez del Cid, R. Amorin, F. Tsou, N. Castro, M.B. García, S. Cheng, A. Scocimarro, M. Rapaccioli, N. Castagneris, G. Malcervelli, P. Levit, O. Carranza, L. Piazzoni, D.L. Kaen, N. Ayala, C. Martin, C. Puparelli, D. Enrico, L. Lupinacci, L. Basbus, A. Perfetti, V. Wainsztein, K. Vera, V. Bluthgen, S. Sena, A. Riso, F. Gayet Preiss, B. Garcia Giner, R. Kowalyszyn, F. Barbaro, M.A. Santa Cruz, N. Bastida, M.M. Rizzo
Journal: Journal of Thoracic Oncology (2024)
P4.11E.23 Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)
Authors: S. Masini, A. Garrido, R. Álvarez, M. Antoñanzas, F. Navarro, C. Traseira, L. Cabezón, C. García, S. Falagan, P. Rocha, J. Mosquera, A. Azkárate, E. García-Lorenzo, M.C. Martin-Soberón, S. Sequero, M. Sereno, Y. Lage, M. Peressini, S. Cortijo, H. Bote, J. Torres-Jiménez, M. Zurera, L. Paz-Ares, J. Zugazagoitia, J. Baena
Journal: Journal of Thoracic Oncology (2024)
P4.14C.08 HIT-MESO: Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma. UK National Proton Radiotherapy Study
Authors: C. Hiley, A. Gosling, K. Durno, P. Patrick, C. Clarke, C. gardiner, P. Shaw, N. Counsell
Journal: Journal of Thoracic Oncology (2024)
P4.11D.011 Evaluating the Impact of Performance Status on Outcomes in Advanced Lung Cancer: A Phase II Clinical Trial
Authors: M.F. Porebski, S.C. Grant, W.J. Petty, J. Ruiz, P. Triozzi, B.J. Levine, J.N. Atkins, K. Khan, D.R. Soto-Pantoja, T.W. Lycan
Journal: Journal of Thoracic Oncology (2024)
P4.11E.01 Real-World First-Line Maintenance Immunotherapy for Nonsquamous Advanced/Metastatic NSCLC without Targetable Mutations
Authors: M. Shah, U. Tapan, K.F. Bell, A. Aziez, X. Sun, M. Du, E. Du, Q. Hua, H. Yang
Journal: Journal of Thoracic Oncology (2024)
P4.11E.21 Predictive Value of Longitudinal Systemic Inflammatory Markers for Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable NSCLC
Authors: X. Tao, Q. Zhang, P. Yuan, S. Wang, J. Ying, N. Li, W. Guo, J. Li, L. Guo, Y. Liu, Z. Zhang, S. Zhao, S. Gao, N. Wu
Journal: Journal of Thoracic Oncology (2024)
P4.11E.26 A Multicenter Retrospective Study Reveals High MET Expression Associated with Superior Benefit from Immunotherapy in Advanced NSCLC Patients
Authors: H. Li, L. Hong, Y. Jin, P. Rocha, R.B. Mora, I.I. Wistuba, L.M. Solis Soto, C.A. Arrechedera, C. Young, N. Vokes, J. Wu, W. Rinsurongkawong, J.J. Lee, D.L. Gibbons, A.A. Vaporciyan, J.V. Heymach, X. Le, Y. Fan, J. Zhang
Journal: Journal of Thoracic Oncology (2024)
P4.11E.28 Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA
Authors: T.S. Samant, H. Struemper, R.C. Franzese, B. Goulooze, M. Muliaditan, M. Melhem, S. Ghosh, M. Fastenrath, N. Stjepanovic, Z. Szijgyarto, C. Rathi, A. Mantero, P. Hanafin, S. Zajic, N. Yanamandra, C-w. Chung, G. Vlahovic
Journal: Journal of Thoracic Oncology (2024)
P4.11D.12 Phase 3 Trial of OSE2101 Versus Docetaxel in Patients with Non-Small Cell Lung Cancer &amp; Secondary Resistance to Immunotherapy
Authors: S.V. Liu, J. Singh, X. Yang, J. D'olimpio, F. Cappuzzo, R. Dziadziuszko, S. Viteri, C. Chevalier, S. Comis, T. Vandewalle, V. Gabarre, F. Montestruc, B. Vasseur, J. Remon, B. Besse
Journal: Journal of Thoracic Oncology (2024)
P4.11D.06 A Phase II Trial of Restorative Microbiota Therapy with Chemoimmunotherapy in Metastatic Non-Small Cell Lung Cancer
Authors: A. Kulkarni, S. Kagalwalla, N. Fujioka, B. Manning, R. Kratzke, A. Khoruts, M.R. Patel
Journal: Journal of Thoracic Oncology (2024)
P4.14C.03 Real-World Prognostic &amp; Predictive Implications of EORTC &amp; MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)
Authors: F.T.H. Wu, M.-F. D’Amours, F. Usman, A. Hussein, E. Bhang, M. Kamali Sarvestani, C.W. Lee, C. Ho
Journal: Journal of Thoracic Oncology (2024)
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study
Authors: Y. Kogure, H. Hashimoto, S. Ikeda, T. Harada, A. Hino, S. Miura, Y. Goto, K. Fujiwara, N. Kaktakami, K. Kubota, N. Murata, M. Mori, T. Abe, N. Yamamoto, H. Saka, M. Kondo
Journal: Journal of Thoracic Oncology (2024)
P4.11E.03 Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)
Authors: D. Huang, Z. Song, J. Qin, D. Zhong, Y. Chen, W. Huang, G. Li, L. Lin, L. Wang
Journal: Journal of Thoracic Oncology (2024)
P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations
Authors: F. Skoulidis, H. Borghaei, E.B. Garon, T.A. Leal, J. Kaufman, S.V. Liu, E. Nadler, S.P. Patel, S. Peters, V. Velcheti, A. Gautam, U. Emeribe, L. Luciani-Silverman, J.V. Heymach
Journal: Journal of Thoracic Oncology (2024)
P4.11E.11 Dosing Regimen for Acasunlimab (DuoBody-PD-L1x4-1BB) In Combination with Pembrolizumab
Authors: G. Bajaj, P. Garrido Castro, E. Felip, C. Helissey, D. Kowalski, B. Besse, L. Paz-Ares, M.J. Chisamore, B. Tan, C. Gorgun, B. de Andrade, A.C. Costa Sá, S. Sridhar, J. Blum, G. Masters, Y. Zhou, S. Feng, C. Thalhauser, N. Pencheva, M. Jure-Kunkel, J. Aerts
Journal: Journal of Thoracic Oncology (2024)
P4.11E.19 The Effect of COVID-19 On Treatment Outcomes in Non-Small Cell Lung Cancer Patients: A Propensity Score Matched Analysis
Authors: W.Y. Aung, A. Sood, L. Hou, J. Elengickal, S.H. Peketi, M. Locke, X. Zhou, A. Sangari, N. Seetharamu
Journal: Journal of Thoracic Oncology (2024)
P4.11E.12 First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial
Authors: Y.-S. Li, J.-J. Yang, Q. Yu, Q. Bu, L. Lin, F. Ning, G. Wu, G. Lin, A. Zang, S. Ma, C. Zhou, A. Liu, Y. Zhao, C. Wang, Y. Yao, G. Han, J. Zhao, Y. Pan, H. Sun, M.-M. Zheng, S.-Y.M. Liu, H.-H. Yan, H.-Y. Tu, Q. Zhou, J. Lv, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC
Authors: L. Liu, J. Liu, Y. Liu, X. Yu, S. Li, B. Li, S. Guo, Y. Zhang, Y. Wang, T. Zheng, W. Han, Y. Xie, L. Zhou, J. Zhang, Y. Zhao, Y. Li, Y. Hu, J. Wang, H. Cao
Journal: Journal of Thoracic Oncology (2024)
P2.11B.02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer
Authors: A. Saini, A. Elkrief, L. Hong, B. Ricciuti, E. Garbo, F. Pecci, M. Makarem, A. Di Federico, M.M. Gandhi, M. Aldea, M. Nishino, L.M. Sholl, N.I. Vokes, A.J. Schoenfeld, M.M. Awad
Journal: Journal of Thoracic Oncology (2024)
P2.17A.01 Treatment Outcomes after Access to Broad Molecular Tests, Targeted Agents and Immunotherapy in NSCLC Patients from Brazil
Authors: F.L.V. Visani, C. Mathias, R.D. Paes, T. Montella, N. Afonso, I. Negreiros, L. Moreira, G. Veloso, M.X. Reis, I. Barcelos, B. Ferrari, C.G. Ferreira, P. De Marchi, R. Dienstmann
Journal: Journal of Thoracic Oncology (2024)
P4.07G.05 Prediction of Quality-of-Life Results after Lung Stereotactic Body Radiotherapy Using Functional Mapping on Gallium-68 Perfusion PET/CT
Authors: F. Lucia, J. Lamour, M. Geier, V. Bourbonne, U. Schick, M. Nebbache, F. Pinot, O. Pradier, G. Le Gal, S. Hennebicq, M. Mauguen, K. Kerleguer, F. Blanc-Beguin, D. Bourhis, P.-Y. Salaun, P.-Y. Le Roux
Journal: Journal of Thoracic Oncology (2024)
P2.11A.20 Metformin Enhances Immune Checkpoint Inhibitor Response in Overweight Lung Cancer Patients: A Retrospective Cohort Study
Authors: S. Kalvapudi, S. Bawek, Y. Vedire, A. Pachimatla, P. Jain, S. Yendamuri
Journal: Journal of Thoracic Oncology (2024)
P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade
Authors: B. Ricciuti, L. Hong, E. Gariazzo, T. Gorria, R. Thummalapalli, N. Awosika, L. Mollica, F. Citarella, M. Gandhi, A. Elkrief, F. Pecci, J. Alessi, A. Di Federico, M. Makarem, A. Saini, M. Aldea, E. Garbo, J.B. Espinar, R. Ferrara, C. Alessio, D. Pinato, A. Schoenfeld, F. Aboubakar Nana, L. Mezquita, G. Metro, N. Vokes, M. Awad
Journal: Journal of Thoracic Oncology (2024)
P2.16C.01 Awareness, Stigma, and Fatalism Towards Cancer Clinical Trials Among Black Individuals Diagnosed with Lung Cancer
Authors: A. Ciupek, S. Stallings, N. Amanna, E. Howell, R.E. Gaskin, J.E. Murrel, A. Allgood, M. Aldrich, N.A. Karim, C.M. Lovly, S.J. Niranjan
Journal: Journal of Thoracic Oncology (2024)
P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy
Authors: L. Wang, S. Su, X. Lv, Y. Liu, F. Chen, J. Shao, B. Liu
Journal: Journal of Thoracic Oncology (2024)
P4.11E.18 Impact of Prophylactic use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancer: A Cohort Study
Authors: C.B. Han, L. Sun, Y. Tian, S.L. Zhang, L.T. Huang, J.T. Ma
Journal: Journal of Thoracic Oncology (2024)
P2.11A.15 Gut Metatranscriptomics Predict Survival in Anti-PD Immunotherapy Treated Advanced-Stage Non-Small Cell Lung Cancer
Authors: D. Dora, P. Kiraly, C. Somodi, B. Ligeti, D. Edit, G. Galffy, Z. Lohinai
Journal: Journal of Thoracic Oncology (2024)
P4.11D.09 Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates
Authors: T. Melkadze, M. Gogishvili, T. Makharadze, E. Arkania, V. Kuchava, K.H. Lee, M. Zhvania, D. Brungs, N. Chikhladze, J.S. Hrom, H.K. Ahn, J. Porter, S. Goldberg, M. Reck, S. Peters, A. Baramidze
Journal: Journal of Thoracic Oncology (2024)
P2.11B.01 Deciphering Immunotherapy Resistance Mechanisms in Metastatic NSCLC, Insights from Plasma Proteomics Analysis
Authors: Y. Brody, E. Jacob, G. Loewenthal, P. Christopoulos, M.A. Schneider, T. Muley, A. Ammendola, I. Koch, N. Reinmuth, M. Lotem, A. Zer, B. Yellin, Y. Elon, I. Sela, A.P. Dicker
Journal: Journal of Thoracic Oncology (2024)
P2.11B.04 Chemotherapy Increases Acquired Resistance to Immunotherapy in NSCLC: A Metanalysis of Aggregate and Individual Patient Data
Authors: S. Oresti, A. Nuccio, F. Salomone, G. Damiano, F.R. Ogliari, S.T. Riva, F.M. Venanzi, L. Mollica, M. Ferrara, N. Fogale, F. Passaretti, L. Papotto, M. Ravasi, M.G. Vigano', A. Bulotta, B. Ricciuti, F. Pecci, V. Torri, M. Cinquini, G. Viscardi, R. Ferrara
Journal: Journal of Thoracic Oncology (2024)
P4.07G.03 Real-World Clinical Outcomes and the Association Between EFS and OS in Early-Stage NSCLC Treated with Primary SBRT
Authors: M.E. Daly, P. Rai, S. Zhang, Y. Song, A. Jiang, J. Li, P. Jiang, C. Gao, J. Signorovitch, A. Arunachalam, A. Song, A. Samkari
Journal: Journal of Thoracic Oncology (2024)
P4.07E.06 Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas
Authors: L. Zhang, H. Qiang, J. Luo, C. Ji, Y. Zhang, Y. Wang, S. Cao, H. Du, J. Wang, B. Li, Y. Zhou, H. Zhong
Journal: Journal of Thoracic Oncology (2024)
P2.11A.25 Clinicogenomic Profile of Different Resistance Patterns to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Authors: L. Hong, M. Aminu, C. Young, W. Rinsurongkawong, H. Li, K. Qin, Y. Elamin, B. Sepesi, D. Gibbons, A. Vaporciyan, J.J. Lee, S. Roy-Chowdhuri, M. Routbort, X. Le, J. Heymach, J. Wu, J. Zhang, N. Vokes
Journal: Journal of Thoracic Oncology (2024)
P4.11D.10 A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, And Atezolizumab in Non-Squamous NSCLC and Brain Metastases
Authors: B. Schluger, T.F. Burns, H. Wang, D.P. Petro, J. Ohr, S.A. Burton, N. McCall, S. Choi, K.G. Abdullah, A. Niranjan, C.G. Hadjipanayis, L.C. Villaruz
Journal: Journal of Thoracic Oncology (2024)
P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%
Authors: N. Frost, R. Ghori, A. Roy, A.T. Nunes, J.C.-H. Yang
Journal: Journal of Thoracic Oncology (2024)
P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update
Authors: M.L. Johnson, E. Girda, D. Sohal, N.J. Lakhani, A.J. Olszanski, L. Fong, M. Kinnaman, H. Han, A. Moesta, Y. Hao, S. Li, S. Ganguly, F. Seebach, M. Mathias, N.H. Segal
Journal: Journal of Thoracic Oncology (2024)
P2.11B.03 Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy
Authors: R. Ferrara, T. Torelli, M. Brambilla, A. Prelaj, C.M. Ciniselli, A. Piva, B. Bassani, E. Jachetti, G. Calareso, V. Duroni, C. Proto, S. Manglaviti, L. Mazzeo, T. Beninato, M. Ganzinelli, A. Bulotta, P. Verderio, B. Ricciuti, C. Bonini, M.C. Garassino, M.P. Colombo, V. Torri, L. Agnelli, G. Lo Russo, S. Sangaletti
Journal: Journal of Thoracic Oncology (2024)
P2.14A.09 Adaptive Reprogramming of Arginine Biosynthesis is an Attractive Target for Modulating the Response to WEE1 Inhibition in Pleural Mesothelioma
Authors: S. Yin, R.A. Schmid, R.-W. Peng, D. Xu, Y. Shu
Journal: Journal of Thoracic Oncology (2024)
P4.07D.01 Neoadjuvant Osimertinib Followed by Radiation And/or Surgery in Stage III EGFR-Mutant NSCLC: An Open-Label, Single-Arm, Phase 2 Study
Authors: N. Peled, W. Kian, B. Krayim, J. Dudnik, S. Keren-Rosenberg, I.S. Granot, H. Nechushtan, N. Heching, O. Rotem, E. Dudnik, I. Lazarev, E. Chernomordikov, W. Shalata, D. Levin, Y. Krutman, K. Lavrenkov, P. Blumenfeld, A.M. Allen, L.C. Roisman
Journal: Journal of Thoracic Oncology (2024)
P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study
Authors: S. Verma, M.D. Vincent, G. Liu, J. Rothenstein, I.B. Menjak, P.K. Cheema, R.A. Juergens, M. Valdes, P. Bains, Y. Wang, P. Wheatley-Price, D.A. Breadner
Journal: Journal of Thoracic Oncology (2024)
P2.11A.03 Association of LIPI with Patterns of Response, Resistance, and Survival in Patients with Metastatic NSCLC Treated with PD(L)-1 Blockade
Authors: E. Caballe, L.A. Cabrera-Miranda, M. Ramos-Ramirez, N. Hernandez-Pedro, J. Lucio-Lozada, C. Castillo-Ruiz, D. Davila-Dupont, C. Izquierdo-Tolosa, D. Flores-Estrada, P. Soberanis-Piña, A.F. Cardona, L.E. Raez, O. Arrieta
Journal: Journal of Thoracic Oncology (2024)
P2.10B.01 Exploratory Analyses of Tusamitamab Ravtansine vs Docetaxel in Previously Treated Non-squamous NSCLC Patients: CARMEN-LC03
Authors: B.C. Cho, J. Cadranel, M. Chadjaa, S. Yoruk, P.A. Dennis, A. Seluzhytsky, L. Charbonnier, L. Wu
Journal: Journal of Thoracic Oncology (2024)
P2.11B.05 Effect of Dysbiosis-Inducing Drugs on the Response to Immune Checkpoint Inhibitors in Patients with NSCLC
Authors: S. Lopes, B. Bertrand, P. Lucile, Q. Creusot, B. Mennecier, G. Pamart, C. Matau, E. Pancreach, M. Beau-Faller, A. Dory, C. Mascaux
Journal: Journal of Thoracic Oncology (2024)
P2.07B.06 Segmentectomy for cIA1-2 Lung Cancer in the Lower Lobe with Solid-Predominant Opacity: Impact on Recurrence and Survival Rates
Authors: M. Endo, J. Suzuki, H. Watanabe, S. Takamori, K. Sato, T. Sasage, M. Nakatsuka, K. Hoshijima, K. Abe, A. Niwa, S. Shiono
Journal: Journal of Thoracic Oncology (2024)
P4.04D.03 Lung Cancer in Those Who Never Smoked Study (luCNeSS) - Preliminary Analysis
Authors: M. Aglan, M. Tammemagi, A. Borondy-Kitts, P.J. Hesketh, K. Rieger-Christ, A.J. Piper-Vallillo
Journal: Journal of Thoracic Oncology (2024)
P2.10A.05 Ipat-Lung: A Multi-Center Phase 2 Study of Ipatasertib Plus Docetaxel in NSCLC Patients who Have Failed or Are Intolerant to 1st Line Immunotherapy
Authors: J. Zhang, C.H. Huang, P.C. Neupane, R. Chuda, R.J. McKittrick, M.R. Allen, Q. Dai, Z. Collins, R. Madan, M.A. Phadnis, C. Zhong, M. Furqan, Z. Hao
Journal: Journal of Thoracic Oncology (2024)
P4.11D.03 Trial in Progress: Phase 1/2 Study of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Solid Tumors
Authors: A.J. Schoenfeld, A. Betof Warner, J.A. Chesney, S.S. Thomas, J.T. Moyers, G.K. In, A.N. Shoushtari, Y. Samhouri, P. Hari, G. Ramsingh, C. Renard, P. Prabhakar, L. Mclaughlin, K. He
Journal: Journal of Thoracic Oncology (2024)
P4.07F.01 Real World Characteristics and Distant Metastasis Free Survival of Patients with Early NSCLC Treated with Chemoimmunotherapy
Authors: K. Schwed, L. Kalesinskas, Q. Yuan, C.A. Keane, E.L. Fidyk, E. Castellanos, A.B. Cohen, K. Harrison, G. Ho, A. Marinescu, A. Desai
Journal: Journal of Thoracic Oncology (2024)
P2.11A.01 Racial/ethnic Differences in Real-World Adverse Events and Survival Among Patients on Immunotherapy for Advanced NSCLC
Authors: G.G. Ho, O. Mbah, X. Wang, K. Schwed, A. Dolor, Q. Zhang, D. Donnelly, K. Magee, P. Yerram, C.A. Ryals
Journal: Journal of Thoracic Oncology (2024)
P2.11A.08 Molecular and Immunological Features Associated with Long-Term Benefit in Metastatic NSCLC Patients Undergoing Immune Checkpoint Blockade
Authors: P. Rocha, R. Bach, L. Masfarre, S. Hernandez, N. Navarro-Gorro, A. Rossell, X. Villanueva, M. Giner, I. Sanchez, M. Galindo, R. del Rey-Vergara, A. Iñañez, B. Sanchéz-Espiridion, W. Lu, A. Acedo-Terrades, P. Berenguer-Molins, A. Sánchez-Font, R. Chalela, V. Curull, Á. Taus, M. Hardy-Werbin, M. Sausen, A. Georgiadis, J. White, J.B. Jackson, L. Moliner, S. Clavé, B. Bellosillo, A. Rovira, I. Wistuba, L.M. Solis Soto, J. Perera-Bel, E. Arriola
Journal: Journal of Thoracic Oncology (2024)
P4.04D.08 Natural History Model for Second Primary Lung Cancer Among Lung Cancer Survivors: Utilizing the U.S. SEER Cancer Registries
Authors: E. Choi, V. Ritter, J.H. Lee, J.T. Wu, K. ten Haaf, C.C. Su, L.M. Backhus, A.N. Leung, H.A. Wakelee, S.S. Han
Journal: Journal of Thoracic Oncology (2024)
P4.07F.05 Low OLFM1/BMP6 Expression Identifies High-Risk Stage I Non-Squamous Non-Small Cell Lung Cancer after Pulmonary Resection
Authors: K. Suda, Y. Yoshida, H. Sato, A. Hamada, M. Yotsukura, K. Shiraishi, R. Hamamoto, Y. Chiba, T. Kohno, Y. Yatabe, S.-I. Watanabe, Y. Tsutani, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2024)
P2.07C.03 Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting
Authors: Z-b. Qiu, Z. Xu, H.-J. Li, J.-H. Yan, J.-Y. Ding, C. Zhang, Y.-L. Wu, W.-Z. Zhong
Journal: Journal of Thoracic Oncology (2024)
P2.07A.04 Clinical Relevance of PD-L1 Expression Levels in Surgically Resected EGFR-Mutant Lung Adenocarcinoma Patients (CReGYT-01 Study)
Authors: F. Kinoshita, K. Nomura, K. Takada, S. Muto, T. Matsubara, Y. Kouki, S. Katsumata, A. Hamada, N. Haratake, K. Fujino, M. Yoshikawa, K. Suzawa, K. Shien, K. Suda, S. Ohara, S. Fukuda, H. Suzuki, T. Okamoto, F. Hirai, K. Aokage, S. Shiono, J. Soh, M. Tsuboi, M. Shimokawa, Y. Ohde, T. Takenaka, T. Yoshizumi
Journal: Journal of Thoracic Oncology (2024)
P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC
Authors: N.B. Leighl, E. Nadal, J.C.-H. Yang, M.C. Garassino, J. Zhao, D. Planchard, B.C. Cho, L. Starkopf, K. Rajagopalan, J.Y. Wu, I. Okamoto
Journal: Journal of Thoracic Oncology (2024)
P4.07E.08 Single-Cell TCR Barcoding and RNA Sequencing Illuminate Distinct Tumor-Draining Lymph Node T Cell Responses to Neoadjuvant PD-1 Blockade
Authors: R. Honigsberg, T. Cruz, L. Yoffe, G. Markowitz, D. Ozgenel, O. Elemento, N. Altorki, V. Mittal, J. Villena-Vargas
Journal: Journal of Thoracic Oncology (2024)
P2.11A.04 Exhaled Breath Biomarkers of Response to Immunotherapy in Advanced Non-Small Lung Cancer
Authors: D.E.O. Reilly, G. Dowling, S. Marks, S. Barry, C. Moloney, L. Moran, R. Kieran, C. Cluxton, J. Moyle, A. Reilly, O. Deac, C. McNevin, D. Hadi, R. Dillon, L. Kirwan, M.P. Barr, S. Cuffe, S. Toomey, B. Hennessy, J. Naidoo
Journal: Journal of Thoracic Oncology (2024)
P2.05C.02 Does the Proposed 9th TNM Offer Improved Prognostic Accuracy after Lung Carcinoma Resection? Preliminary Analysis Results
Authors: P.H. Kaluzynski, M. Knetki-Wroblewska, A. Szpechcinski, P. Rudzinski, M. Pawlica, R. Langfort, T. Orlowski, M. Szolkowska
Journal: Journal of Thoracic Oncology (2024)
P4.07G.01 Incidence of and Outcomes of Second Primary Lung Cancer after Resection for Screen-Detected Lung Cancer
Authors: A. Potter, S. Venkateswaran, Q. Guo, P. Senthil, D. Wang, P. Furlow, M. Lanuti, C.-F.J. Yang
Journal: Journal of Thoracic Oncology (2024)
P2.07C.02 Prognostic Impact of Adjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer Following Neoadjuvant Immunotherapy
Authors: Y. Dong, L. Xu, H. Si, J. Wu, T. Chen, J. Wen, H. Xie, Y. She, D. Zhao, C. Chen
Journal: Journal of Thoracic Oncology (2024)